Unicycive's OLC Faces Manufacturing Hurdle
FDA Issues Second CRL for Unicycive's Dialysis Drug Citing Manufacturing Vendor Deficiencies
Key Points
The NDA for oxylanthanum carbonate is supported by data from three clinical studies (Phase 1 in healthy volunteers, a bioequivalence study in healthy volunteers, and a tolerability study in CKD patients on dialysis), as well as preclinical studies and chemistry, manufacturing and controls data.
The CRL reiterates deficiencies at the same third-party manufacturing vendor cited in the June 2025 CRL, and the FDA did not conduct an inspection of that facility during the resubmission review.
Unicycive had a Type A meeting with the FDA in September 2025 to discuss milestones and progress toward resolving vendor deficiencies and ensuring inspection readiness.
Investor reaction was negative, with shares sliding about 36–37% in premarket trading after the CRL was issued.
The U.S. Food and Drug Administration has rejected Unicycive Therapeutics' kidney drug for a second time, issuing a Complete Response Letter for oxylanthanum carbonate on June 30, 2026. The FDA again pointed to manufacturing deficiencies at the same third-party vendor cited in its first rejection a year ago — and this time, did not even inspect the facility during its review, according to Reuters.
Investors punished the news hard. Shares of Unicycive (Nasdaq: UNCY) dropped roughly 36% in premarket trading, falling from a close of $7.70 to as low as $3.81, according to Benzinga. The FDA raised no concerns about the drug's safety or efficacy and asked for no new clinical data — making the manufacturing vendor the sole barrier to approval.
Same Vendor, Same Problem, One Year Later
The first CRL arrived on June 30, 2025. The FDA flagged deficiencies at a third-party manufacturer. No safety or efficacy issues were raised. Unicycive held a Type A meeting with the FDA in September 2025 — a formal session to map out the vendor's path to fixing the problems. The FDA did not flag concerns about the vendor's progress at that stage, according to Morningstar.
Based on what it called perceived progress by the vendor, Unicycive resubmitted its NDA in December 2025. The FDA accepted it in January 2026, setting a review deadline of June 29, 2026. But when that date arrived, the agency issued a second CRL citing the exact same deficiencies — without having conducted a facility inspection at all, GlobeNewswire reported.
Labeling Talks on June 29 Raised False Hope
Adding to investor frustration: on June 29 — the day before the CRL — Unicycive received FDA communication about carton and container labeling, according to Conexiant. Labeling discussions typically signal that an approval is close. Many investors read the update as a positive sign. The rejection the next day caught them off guard.
CEO Shalabh Gupta said the company is still in "active and ongoing discussion with the FDA regarding label and packaging" and called the manufacturing issue solvable. "We remain confident in the efficacy and safety of OLC," he said, according to Fierce Pharma. The FDA's decision not to request new clinical data supports his position — the drug works, it just can't get made to the FDA's standard yet.
A Drug Built to Cut the Pill Burden for Dialysis Patients
Oxylanthanum carbonate targets hyperphosphatemia — dangerously high phosphorus levels that affect about 75% of U.S. dialysis patients with chronic kidney disease. Current treatments force patients to take as many as 9 to 10 phosphate binder pills a day. OLC uses nanoparticle technology to shrink that to roughly 3 tablets, according to GlobeNewswire.
The NDA is backed by three clinical studies: a Phase 1 trial in healthy volunteers, a bioequivalence study comparing OLC to the existing drug Fosrenol, and a tolerability study in CKD patients on dialysis. Unicycive used the 505(b)(2) regulatory pathway, which lets a company build on the FDA's prior approval of a related drug to speed up review. The global market for phosphate binders is estimated at more than $2.5 billion, with the U.S. accounting for over $1 billion, per Unicycive's SEC filings.
Cash Runway and Next Steps Under Pressure
Unicycive ended 2025 with $41.3 million in cash, according to Morningstar. A third submission attempt will cost more time and money. The company now faces a key decision: keep waiting for the original vendor to fix its issues, or shift production to a second manufacturing vendor that has already made OLC drug product.
The Charlotte Observer and other outlets noted this is the second consecutive rejection tied entirely to manufacturing — not science. Analysts and retail investors have grown skeptical of management's ability to oversee its supply chain, according to Morningstar. Unicycive says it remains "optimistic that there will be a successful inspection" of the vendor. The timeline for a third submission has not been announced.
Sentiment
Mostly NegativePublishers
12
Articles
53
Reach
65
